{"id":399187,"date":"2025-05-25T01:05:00","date_gmt":"2025-05-24T23:05:00","guid":{"rendered":"https:\/\/medizinonline.com\/citochine-th2-in-primo-piano-punti-di-attacco-collaudati-e-nuovi\/"},"modified":"2025-05-24T23:22:13","modified_gmt":"2025-05-24T21:22:13","slug":"citochine-th2-in-primo-piano-punti-di-attacco-collaudati-e-nuovi","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/it\/citochine-th2-in-primo-piano-punti-di-attacco-collaudati-e-nuovi\/","title":{"rendered":"Citochine Th2 in primo piano: punti di attacco collaudati e nuovi"},"content":{"rendered":"\n<p><strong>La gamma di terapie con anticorpi per la dermatite atopica (AD) si \u00e8 ampliata ancora una volta in Europa. Oltre a dupilumab e tralokinumab, lebrikizumab \u00e8 un altro biologico disponibile in questo Paese che interviene in modo specifico nella cascata infiammatoria e ha un profilo di sicurezza impressionante. Nell&#8217;UE, anche il nemolizumab \u00e8 stato recentemente autorizzato per l&#8217;AD.    <\/strong><\/p>\n\n\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fcitochine-th2-in-primo-piano-punti-di-attacco-collaudati-e-nuovi%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>La gamma di terapie con anticorpi per la dermatite atopica (AD) si \u00e8 ampliata ancora una volta in Europa. Oltre a dupilumab e tralokinumab, lebrikizumab \u00e8 un altro biologico disponibile&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fcitochine-th2-in-primo-piano-punti-di-attacco-collaudati-e-nuovi%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":399191,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Biologici per la dermatite atopica  ","footnotes":""},"category":[11343,11351,11452,11522,11550,11515],"tags":[65594,82414,82415,12293,82412,12649,13478,16227,82413,82411,65855,13320],"powerkit_post_featured":[],"class_list":["post-399187","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allergologia-e-immunologia-clinica","category-dermatologia-e-venereologia","category-farmacologia-e-tossicologia","category-rapporti-del-congresso","category-rx-it","category-studi","tag-adtralza-it","tag-arcadia-it","tag-avvocato","tag-biologici","tag-citochine-th2","tag-dermatite-atopica-it","tag-dupilumab-it","tag-dupixent-it","tag-ebglyss-it","tag-lebrikizumab-it","tag-nemolizumab-it","tag-tralokinumab-it","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-02 16:49:32","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"it_IT","wpml_translations":{"pt_PT":{"locale":"pt_PT","id":399186,"slug":"citocinas-th2-em-foco-pontos-de-ataque-comprovados-e-novos","post_title":"Citocinas Th2 em foco: pontos de ataque comprovados e novos","href":"https:\/\/medizinonline.com\/pt-pt\/citocinas-th2-em-foco-pontos-de-ataque-comprovados-e-novos\/"},"es_ES":{"locale":"es_ES","id":399195,"slug":"citocinas-th2-en-el-punto-de-mira-puntos-de-ataque-probados-y-nuevos","post_title":"Citocinas Th2 en el punto de mira: puntos de ataque probados y nuevos","href":"https:\/\/medizinonline.com\/es\/citocinas-th2-en-el-punto-de-mira-puntos-de-ataque-probados-y-nuevos\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/399187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/comments?post=399187"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/399187\/revisions"}],"predecessor-version":[{"id":401787,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/399187\/revisions\/401787"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media\/399191"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media?parent=399187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/category?post=399187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/tags?post=399187"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/powerkit_post_featured?post=399187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}